Exact Mass: 676.4233340000001
Exact Mass Matches: 676.4233340000001
Found 303 metabolites which its exact mass value is equals to given mass value 676.4233340000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Actein
PA(13:0/5-iso PGF2VI)
C34H61O11P (676.3951285999999)
PA(13:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(13:0/5-iso PGF2VI), in particular, consists of one chain of one tridecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(5-iso PGF2VI/13:0)
C34H61O11P (676.3951285999999)
PA(5-iso PGF2VI/13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/13:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of tridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(14:1(9Z)/18:1(12Z)-2OH(9,10))
PA(14:1(9Z)/18:1(12Z)-2OH(9,10)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/18:1(12Z)-2OH(9,10)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 9,10-hydroxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(12Z)-2OH(9,10)/14:1(9Z))
PA(18:1(12Z)-2OH(9,10)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-2OH(9,10)/14:1(9Z)), in particular, consists of one chain of one 9,10-hydroxy-octadecenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(a-13:0/5-iso PGF2VI)
C34H61O11P (676.3951285999999)
PA(a-13:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-13:0/5-iso PGF2VI), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(5-iso PGF2VI/a-13:0)
C34H61O11P (676.3951285999999)
PA(5-iso PGF2VI/a-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/a-13:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(i-13:0/5-iso PGF2VI)
C34H61O11P (676.3951285999999)
PA(i-13:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-13:0/5-iso PGF2VI), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(5-iso PGF2VI/i-13:0)
C34H61O11P (676.3951285999999)
PA(5-iso PGF2VI/i-13:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/i-13:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] tetradecanoate
Actein
Actein is a triterpenoid. It has a role as a metabolite. Actein is a natural product found in Actaea elata, Actaea cimicifuga, and other organisms with data available. See also: Black Cohosh (part of). A natural product found in Actaea racemosa.
4a-[2-(5-ethyl-3,6-dihydro-2H-pyridin-1-yl)-ethyl]-4-{3-[2-(5-ethyl-3,6-dihydro-2H-pyridin-1-yl)-ethyl]-indol-2-yl}-3,4,4a,9-tetrahydro-2H-carbazole-1,4-dicarboxylic acid dimethyl ester|Presecamin|Presecamine
1??,3??-Hydroxyimberbic acid-23-O-??-L-4-acetylrhamnopyranoside
1-Ac,23-O-rhamnopyranoside-(1alpha,3beta)-1,3,23-Trihydroxy-12-oleanen-29-oic acid
(23R,24R)-16beta,23;16alpha,24-diepoxy-12beta-acetoxy-cycloart-7-en-3beta,15alpha,25-triol 3-O-beta-D-xylopyranoside
1-O-[2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranosyl]hexadecanol|cupanioside
3beta-O-(beta-D-glucuronopyranosyl)-olean-12-ene-28,29-dioic acid 29-methyl ester|coryternic acid 3-O-beta-D-glucuronopyranoside
hederagenin-3-O-beta-D-glucuronopyranoside 6-O-methyl ester
3beta,23-dihydroxy-urs-12-en-28-oic acid 3-O-beta-D-glucuronopyranoside 6-O-methyl ester
(2S,4aR,5aS,7aR,7bR,11R,12aS,13R,13aS)-11-(2-butoxypropan-2-yl)-13-hydroxy-1,1,7a,8,13a-pentamethyloctadecahydro-10,12a-epoxycyclopropa[1,8a]naphtho[2,1:4,5]indeno[2,1-b]oxepin-2-yl beta-D-xylopyranoside|(3beta,15alpha,23R,24S)-15-hydroxy-25-butyl-16,23:16,24-diepoxy-9,19-cyclolanosta-3-O-beta-D-xylopyranoside|25-O-butylcimigenol-3-O-beta-D-xylopyranoside
(20S*,22R*,23S*,24R*)-16beta:23:22:25-diepoxy-3beta,24-dihydroxy-23-methoxy-9,19-cyclolanostane-3-O-beta-D-(4-acetyl)xylopyranoside|soulieoside D
[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] tetradecanoate
[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] tetradecanoate_major
[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] tetradecanoate_87.6\\%
[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] tetradecanoate_minor
[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] tetradecanoate_85.2\\%
[(2R,3R,4S,5S,6R)-3-acetyloxy-2-(acetyloxymethyl)-5-hexanoyloxy-6-[(2S,3R)-2,3,4-trihydroxybutoxy]oxan-4-yl] tetradecanoate_89.9\\%
Prostaglandin D2-biotin
C36H60N4O6S (676.4233340000001)
(2S,3R)-2,3,4-Trihydroxybutyl 4,6-di-O-acetyl-2-O-hexanoyl-3-O-tetradecanoyl-?-D-mannopyranoside
Rapacuronium Bromide
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant Rapacuronium bromide (Org 9487), a non-depolarizing neuromuscular blocker, is an allosteric modulator of muscarinic acetylcholine receptor (mAChR)[1].
(5R)-3-O-[(2E)-3-carboxyprop-2-enoyl]-2,4-dideoxy-1-C-{(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4R,6R,9S,10S,11R,12R,14R)-10-hydroxy-3-methoxy-7,9,11,13,15-pentamethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl}-4,5-dimethyl-beta-L-erythro-pentopyranose
N-[5-[3-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]propanoylamino]pentyl]-5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanamide
[1-decoxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] dodecanoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (Z)-heptadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (Z)-hexadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (Z)-tetradec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] decanoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (Z)-tridec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] tridecanoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] tetradecanoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (Z)-pentadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] undecanoate
[(4E,8E,12E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyheptadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
C38H65N2O6P (676.4580000000001)
[(4E,8E,12E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]pentadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
C38H65N2O6P (676.4580000000001)
[(4E,8E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]pentadeca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
C38H65N2O6P (676.4580000000001)
[(4E,8E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]trideca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
C38H65N2O6P (676.4580000000001)
[(E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyundec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C38H65N2O6P (676.4580000000001)
[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[(E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]non-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C38H65N2O6P (676.4580000000001)
[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (15Z,18Z)-hexacosa-15,18-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (13Z,16Z)-tetracosa-13,16-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (15Z,18Z)-hexacosa-15,18-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (13Z,16Z)-tetracosa-13,16-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (Z)-pentadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-hexadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
2,3-bis[[(6Z,9Z)-dodeca-6,9-dienoyl]oxy]propyl (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate
2,3-bis[[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy]propyl (9Z,11Z,13Z)-hexadeca-9,11,13-trienoate
[3-[(6Z,9Z)-dodeca-6,9-dienoyl]oxy-2-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxypropyl] (7Z,9Z,11Z,13Z)-hexadeca-7,9,11,13-tetraenoate
[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(5Z,8Z,11Z)-tetradeca-5,8,11-trienoyl]oxypropyl] (5Z,8Z,11Z)-tetradeca-5,8,11-trienoate
[2-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-3-[(Z)-dodec-5-enoyl]oxypropyl] (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-pentadec-9-enoate
[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoate
[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-pentadec-9-enoate
[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (9E,11E)-octadeca-9,11-dienoate
[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (10E,13E,16E)-nonadeca-10,13,16-trienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoate
[1-[(E)-tridec-8-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,9E)-nonadeca-7,9-dienoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (6E,9E)-octadeca-6,9-dienoate
2-[hydroxy-[2-hydroxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-6,9,12,15,18,21,24,27-octaenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
1-(1Z-hexadecenyl)-2-(9Z-tetradecenoyl)-glycero-3-phospho-(1-sn-glycerol)
1-(9Z,12Z-heptadecadienoyl)-2-dodecanoyl-glycero-3-phospho-(1-sn-glycerol)
1-dodecanoyl-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phospho-(1-sn-glycerol)
Hygrolidin
A macrolide consisting resulting from the formal lactonisation of the carboxy group of (2E,4E,6R,7S,8S,10E,12E,14S,15R,16S,17R,18S)-18-[(2R,4R,5S,6R)-4-{[(2E)-3-carboxyprop-2-enoyl]oxy}-2-hydroxy-5,6-dimethyltetrahydro-2H-pyran-2-yl]-7,15,17-trihydroxy-14-methoxy-2,4,6,8,10,16-hexamethylnonadeca-2,4,10,12-tetraenoic acid with the hydroxy group at position 15. It is active against SV40 tumour cells, and inhibits the growth of solid tumour-derived cell lines such as DLD-1 human colon cancer cells with increased cells in G1 and S phases.
phosphatidylserine 28:1(1-)
A 3-sn-phosphatidyl-L-serine(1-) in which the acyl groups at C-1 and C-2 contain 28 carbons in total and 1 double bond.
TG(40:9)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
methyl (1s,12r,14r,18s)-12-[(1r,15s,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-6-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
methyl (1s,12s,14s,15e,18s)-12-[(1s,9s,12s,13s,15r,20r)-12-ethyl-8-methyl-14-oxa-8,17-diazahexacyclo[10.7.1.0¹,⁹.0²,⁷.0¹³,¹⁵.0¹⁷,²⁰]icosa-2,4,6-trien-4-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
(1s,4s,5s,6s,8r,10r,11r,13s,17r,18r,19r,22s)-6-hydroxy-22-isopropyl-4,9,9,13,17-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-20-oxahexacyclo[17.2.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tricos-14-en-11-yl acetate
(2r,3r,4s,5s,6r)-3-(acetyloxy)-2-[(acetyloxy)methyl]-5-[(2-methylpropanoyl)oxy]-6-[(2r,3s)-2,3,4-trihydroxybutoxy]oxan-4-yl hexadecanoate
5-{[7-(acetyloxy)-1-[2-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
2,3-dihydroxy-2-methyl-6-[6,9,14-tris(acetyloxy)-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]heptan-4-yl acetate
(1s,1'r,2r,3'r,4s,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
methyl 3-[(3s,3ar,4r,5ar,6s,7s,9ar,9br)-4-{[(2s,3r,4s,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-3-[(2s)-2-hydroxy-6-methyl-5-methylideneheptan-2-yl]-6,9a,9b-trimethyl-7-(prop-1-en-2-yl)-decahydrocyclopenta[a]naphthalen-6-yl]propanoate
2-{[22-(2-butoxypropan-2-yl)-2-hydroxy-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol
(3as,7as)-1-[(2s)-2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-phenylpropanoyl]-6-hydroxy-n-{4-[n-(3-methylbut-2-en-1-yl)carbamimidamido]butyl}-octahydroindole-2-carboximidic acid
5-[(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl 2-[4,10-dihydroxy-8-(3-hydroxypentan-2-yl)-3,5,9,11-tetramethyl-1,7-dioxaspiro[5.5]undecan-2-yl]propanoate
(2s,4r,5s,6r)-5-{[(2s,4s,5r,6r)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl (2s)-2-[(2s,3r,4s,5r,6s,8r,9r,10s,11s)-4,10-dihydroxy-8-[(2s,3s)-3-hydroxypentan-2-yl]-3,5,9,11-tetramethyl-1,7-dioxaspiro[5.5]undecan-2-yl]propanoate
(1r,4s,5s,6s,8s,10r,11r,13s,17r,18r,19s,22s)-6-hydroxy-22-isopropyl-4,9,9,13,17-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-20-oxahexacyclo[17.2.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tricos-14-en-11-yl acetate
3-(acetyloxy)-2-[(acetyloxy)methyl]-5-[(2-methylpropanoyl)oxy]-6-(2,3,4-trihydroxybutoxy)oxan-4-yl hexadecanoate
1α,3β-hydroxyimberbicacid-23-o-α-l-4-acetyl-rhamnopyranoside
{"Ingredient_id": "HBIN002286","Ingredient_name": "1\u03b1,3\u03b2-hydroxyimberbicacid-23-o-\u03b1-l-4-acetyl-rhamnopyranoside","Alias": "NA","Ingredient_formula": "C38H60O10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10225","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
23-o-acetylshengmanol-3-o-alpha-l-arabinopyranoside
{"Ingredient_id": "HBIN004141","Ingredient_name": "23-o-acetylshengmanol-3-o-alpha-l-arabinopyranoside","Alias": "23-o-acetylshengmanol 3-o-\u03b1-l-arabinopyrano-side","Ingredient_formula": "C38H60O10","Ingredient_Smile": "CC(CC(C)(C1C(O1)(C)C)OC(=O)C)C2C(=O)C(C3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C)OC7C(C(C(CO7)O)O)O)C)C)O","Ingredient_weight": "676.9 g/mol","OB_score": "21.08968048","CAS_id": "NA","SymMap_id": "SMIT12813;SMIT14165","TCMID_id": "512","TCMSP_id": "MOL011994","TCM_ID_id": "NA","PubChem_id": "12045947","DrugBank_id": "NA"}
acetylacetol 3-o-arabinoside
{"Ingredient_id": "HBIN014443","Ingredient_name": "acetylacetol 3-o-arabinoside","Alias": "NA","Ingredient_formula": "C37H56O11","Ingredient_Smile": "NA","Ingredient_weight": "676.843","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7225","PubChem_id": "NA","DrugBank_id": "NA"}
21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-7-[(3,4,5-trihydroxyoxan-2-yl)oxy]-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacos-2-en-14-yl acetate
7-hydroxy-3'-(2-hydroxypropan-2-yl)-4,6,12,17,17-pentamethyl-18-[(3,4,5-trihydroxyoxan-2-yl)oxy]-9-oxaspiro[hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosane-8,2'-oxiran]-13-en-3-yl acetate
1,3-bis(acetyloxy)-7-(3-ethenyl-4-hydroxybut-2-en-1-yl)-5,10-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-9-yl tetradecanoate
4,5-bis(acetyloxy)-6-{[2-(hexadecyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-2-methyloxan-3-yl acetate
(5as,5br,7ar,9r,10r,11as,11bs)-11a-(hydroxymethyl)-3-isopropyl-3a,5a,5b,8,8-pentamethyl-1-oxo-9-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h,3h,4h,5h,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-cyclopenta[a]chrysen-10-yl acetate
(1r,3as,7r,8r,9as,11ar)-7-(acetyloxy)-1-[(2r,5r)-5,6-dihydroxy-6-methylheptan-2-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-8-yl 1-methyl 3-hydroxy-3-methylpentanedioate
6-hydroxy-22-isopropyl-4,9,9,13,17-pentamethyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-20-oxahexacyclo[17.2.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tricos-14-en-11-yl acetate
3-(acetyloxy)-2-[(acetyloxy)methyl]-5-(butanoyloxy)-6-(2,3,4-trihydroxybutoxy)oxan-4-yl hexadecanoate
(1s,3r,3's,4r,5r,6s,7r,8r,10s,12s,16r,18s,21r)-7-hydroxy-3'-(2-hydroxypropan-2-yl)-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxaspiro[hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosane-8,2'-oxiran]-13-en-3-yl acetate
7-(acetyloxy)-1-(5,6-dihydroxy-6-methylheptan-2-yl)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-8-yl 1-methyl 3-hydroxy-3-methylpentanedioate
(1s,1'r,2r,3'r,4s,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3s,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
(3s,3ar,5as,5br,7ar,9r,10r,11as,11bs)-11a-(hydroxymethyl)-3-isopropyl-3a,5a,5b,8,8-pentamethyl-1-oxo-9-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h,3h,4h,5h,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-cyclopenta[a]chrysen-10-yl acetate
(1r,3s,5s,6ar,7r,8r,9s,10s,10ar)-1,3-bis(acetyloxy)-7-[(2z)-3-ethenyl-4-hydroxybut-2-en-1-yl]-5,10-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-9-yl tetradecanoate
13-(acetyloxy)-9-hydroperoxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,7-dien-14-yl hexadecanoate
(2r,3r,4s,5s,6r)-3-(acetyloxy)-2-[(acetyloxy)methyl]-5-(butanoyloxy)-6-[(2r,3s)-2,3,4-trihydroxybutoxy]oxan-4-yl hexadecanoate
(3r,3ar,5as,5br,7ar,9r,10r,11as,11bs)-11a-(hydroxymethyl)-3-isopropyl-3a,5a,5b,8,8-pentamethyl-1-oxo-9-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h,3h,4h,5h,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-cyclopenta[a]chrysen-10-yl acetate
(2s,3r,4s,5r)-2-{[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22s)-22-(2-butoxypropan-2-yl)-2-hydroxy-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol
(1s,3r)-3-hydroxy-3,5,5-trimethyl-4-[(3e,5e,7e,9e,11e,13e,15e)-3,7,12,16-tetramethyl-17-oxo-18-[(1s,2r,4s)-1,2,4-trihydroxy-2,6,6-trimethylcyclohexyl]octadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]cyclohexyl acetate
3-hydroxy-3,5,5-trimethyl-4-[3,7,12,16-tetramethyl-17-oxo-18-(1,2,4-trihydroxy-2,6,6-trimethylcyclohexyl)octadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene]cyclohexyl acetate
4,5-dihydroxy-6-({21-hydroxy-22-methoxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl}oxy)oxan-3-yl acetate
(1r,2s,6r,9r,10r,11r,13s,14r,15r)-13-(acetyloxy)-9-hydroperoxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,7-dien-14-yl hexadecanoate
(3s,4s,6r)-2,3-dihydroxy-2-methyl-6-[(1s,3r,6s,8r,9s,11s,12s,14s,15r,16r)-6,9,14-tris(acetyloxy)-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]heptan-4-yl acetate
(2s,3s,4r,5r,6s)-4,5-bis(acetyloxy)-6-{[(2r,3r,4s,5s,6r)-2-(hexadecyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-2-methyloxan-3-yl acetate
(2s,3s,4r,5r)-6-{[(3s,4r,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3-ethoxy-4,5-dihydroxyoxane-2-carboxylic acid
methyl (1s,12r,14r,15e,18s)-12-[(1r,15s,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-6-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate
(1r,3s,5s,6ar,7r,8r,9s,10s,10ar)-1,3-bis(acetyloxy)-7-[(2z)-3-ethenyl-4-hydroxybut-2-en-1-yl]-5,9-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl tetradecanoate
(2s,4r,5r,6r)-5-{[(2s,4s,5r,6r)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl (2s)-2-[(2s,3s,4r,5s,6r,8s,9s,10r,11r)-4,10-dihydroxy-8-[(2r,3r)-3-hydroxypentan-2-yl]-3,5,9,11-tetramethyl-1,7-dioxaspiro[5.5]undecan-2-yl]propanoate
(1s,3r,3's,4r,5r,6s,7r,8s,10s,12s,16r,18s,21r)-7-hydroxy-3'-(2-hydroxypropan-2-yl)-4,6,12,17,17-pentamethyl-18-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-9-oxaspiro[hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosane-8,2'-oxiran]-13-en-3-yl acetate
(2s,3as,6s,7as)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-phenylpropanoyl]-6-hydroxy-n-{4-[n-(3-methylbut-2-en-1-yl)carbamimidamido]butyl}-octahydroindole-2-carboximidic acid
(1r,1'r,2r,3'r,4s,4'r,5s,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
6,9-dimethyl (6r,9r)-10-[2-(3-ethyl-5,6-dihydro-2h-pyridin-1-yl)ethyl]-6-{3-[2-(3-ethyl-5,6-dihydro-2h-pyridin-1-yl)ethyl]-1h-indol-2-yl}-7h,8h,9h-pyrido[1,2-a]indole-6,9-dicarboxylate
methyl 3-(4-{[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}-3-(2-hydroxy-6-methyl-5-methylideneheptan-2-yl)-6,9a,9b-trimethyl-7-(prop-1-en-2-yl)-decahydrocyclopenta[a]naphthalen-6-yl)propanoate
5-{[(1r,3ar,7r,8r,9as,11ar)-7-(acetyloxy)-1-[(2r,6r)-2-hydroxy-6-(2-hydroxypropan-2-yl)oxan-3-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
(1'r,2r,4'r,5s,5'r,10's,12's,13's,16'r,21'r)-4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-{[(2s)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
(1r,4s,5s,6s,8r,10r,11r,13s,17r,18r,19s,22s)-6-hydroxy-22-isopropyl-4,9,9,13,17-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-20-oxahexacyclo[17.2.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tricos-14-en-11-yl acetate
(3r,4r,5r,6s)-4,5-dihydroxy-6-{[(1s,2s,5r,7s,10r,12s,15r,16r,17s,18r,21r,22r,24s)-21-hydroxy-22-methoxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl]oxy}oxan-3-yl acetate
(1s,1'r,2r,3'r,4s,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
(1r,4s,5s,6s,8r,10r,11r,13s,17r,18s,19s,22s)-6-hydroxy-22-isopropyl-4,9,9,13,17-pentamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-20-oxahexacyclo[17.2.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tricos-14-en-11-yl acetate
11a-(hydroxymethyl)-3-isopropyl-3a,5a,5b,8,8-pentamethyl-1-oxo-9-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h,3h,4h,5h,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-cyclopenta[a]chrysen-10-yl acetate
3-[({[(1s)-1-[(4-carbamimidamidobutyl)-c-hydroxycarbonimidoyl]-3-methylbutyl]-c-hydroxycarbonimidoyl}methyl)(sulfo)amino]-n-(5-carbamimidamidopentyl)decanimidic acid
C29H60N10O6S (676.4417780000001)